- Q3 2021 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptOct 22, 2021円3841 (-0.93%)Earnings
- Chugai Pharmaceutical Co Ltd Information Meeting on RONAPREVE TranscriptAug 26, 2021
- Q2 2021 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptJul 26, 2021円4176 (+1.19%)Earnings
- Chugai Pharmaceutical Co Ltd Information Meeting on Polivy TranscriptJun 03, 2021
- Q1 2021 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptApr 22, 2021円4388 (+3.74%)Earnings
- Full Year 2020 Chugai Pharmaceutical Co Ltd Earnings Presentation TranscriptFeb 04, 2021
- Chugai Pharmaceutical Co Ltd Digital Strategy Meeting TranscriptDec 02, 2020
- Q3 2020 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptOct 22, 2020円4156 (-3.46%)Earnings
- Chugai Pharmaceutical Co Ltd ESG Presentation TranscriptSep 29, 2020
- Chugai Pharmaceutical Co Ltd Information Meeting on ENSPRYNG Subcutaneous Injection TranscriptSep 14, 2020
- Q2 2020 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptJul 27, 2020円5095 (-1.96%)Earnings
- Q1 2020 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptApr 23, 2020円4410 (-0.38%)Earnings
- Full Year 2019 Chugai Pharmaceutical Co Ltd Earnings Presentation TranscriptJan 31, 2020
- Chugai Pharmaceutical Co Ltd Antibody Engineering Technologies Information Meeting TranscriptDec 09, 2019
- Q3 2019 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptOct 24, 2019円2830 (+1.07%)Earnings
- Chugai Pharmaceutical Co Ltd Information Meeting on Rozlytrek TranscriptSep 05, 2019
- Q2 2019 Chugai Pharmaceutical Co Ltd Earnings Presentation TranscriptJul 26, 2019
- Chugai Pharmaceutical Co Ltd FoundationOne CDx Information Meeting TranscriptJul 04, 2019
- Chugai Pharmaceutical Co Ltd ESG Presentation TranscriptJun 18, 2019
- Q1 2019 Chugai Pharmaceutical Co Ltd Earnings Call TranscriptApr 24, 2019円2293.33 (+0.44%)Earnings
Q2 2021 Chugai Pharmaceutical Co Ltd Earnings Call Transcript
I am Dr. Osamu Okuda, President and CEO of Chugai Pharmaceutical. Let me give you the financial overview of the second quarter of fiscal 2021.
Please take a look at Page 5. Revenues from January through June totaled JPY 390.2 billion, up 6.0% year-on-year. The operating profit and net income for the second quarter soared by more than 15% from the year before. We started the first quarter with a drop in both revenues and profit but turning to positive year-on-year growth in revenues and profits for the first half.
Looking at the progress against the full year forecast. Domestic sales and ROI exceeded the forecast made at the beginning of the year. In particular, the growth in ROI was associated with the growth in overseas local sales of in-house products and, therefore, directly contributed to the profits. As a result, both operating profit and net income showed steady growth that surpassed the initial forecast.
As I explained in the next slide, in addition to those factors, there are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)